ConductScience.org, home

Paper86136

Antitumour effect of cimetidine.

Armitage JO and 1 other. Lancet, 1979. Cited by 77 papers, by iCite.

Cite this record

ConductScience Library. Antitumour effect of cimetidine. Papers, record 86136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/86136

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antitumour effect of cimetidine.
PubMed
Journal
Lancet
PubMed
Year
1979
PubMed
Publication types
Case Reports, Letter
PubMed
Citations, by iCite
77
iCite
Relative citation ratio, by iCite
2.75
iCite
Revised in PubMed
2019-06-10
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Armitage JOJ O
2Sidner RDR D

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CimetidineMajor topic
GuanidinesMajor topic
NeoplasmsMajor topic
Aged
Brain Neoplasms
Carcinoma
Carcinoma, Bronchogenic
Female
Gastroesophageal Reflux
Head and Neck Neoplasms
Humans
Lung Neoplasms
Male
Middle Aged
Neck Muscles
Neoplasm Metastasis
Neoplasm Regression, Spontaneous
Radiography
Soft Tissue Neoplasms

Source PubMed

Download CSV of topics

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.

PMIDTitleJournalYearIn PapersSource
30250558Inhibition of histamine receptor H3R suppresses prostate cancer growth, invasion and increases apoptosis via the AR pathway.Oncol Lett2018https://conductscience.org/library/papers/30250558PubMed
27739410Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?Molecules2016https://conductscience.org/library/papers/27739410PubMed
25525463Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent.Ecancermedicalscience2014https://conductscience.org/library/papers/25525463PubMed
22895966Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer.Cochrane Database Syst Rev2012https://conductscience.org/library/papers/22895966PubMed
20375653Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability.Keio J Med2010https://conductscience.org/library/papers/20375653PubMed
11870499Cimetidine in colorectal cancer--are the effects immunological or adhesion-mediated?Br J Cancer2002https://conductscience.org/library/papers/11870499PubMed
8353038Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists.Br J Cancer1993https://conductscience.org/library/papers/8353038PubMed
8102321Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8102321PubMed
8063222Gastric cancer risk after vagotomy.Gut1994https://conductscience.org/library/papers/8063222PubMed
7828988Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth.Gut1994https://conductscience.org/library/papers/7828988PubMed
6511283The role of histamine antagonists on the development of experimental cancer in the rat.Ir J Med Sci1984https://conductscience.org/library/papers/6511283PubMed
6281143Mitogen stimulation of peripheral blood lymphocytes of duodenal ulcer patients during treatment with cimetidine or ranitidine.Gut1982https://conductscience.org/library/papers/6281143PubMed
6128996Histamine receptor antagonism and anti-tumour activity.Br J Cancer1982https://conductscience.org/library/papers/6128996PubMed
3350837Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.J Cancer Res Clin Oncol1988https://conductscience.org/library/papers/3350837PubMed
3160225In vivo and in vitro anti-tumour activity of dimaprit.Agents Actions1985https://conductscience.org/library/papers/3160225PubMed
3114265Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma.J Cancer Res Clin Oncol1987https://conductscience.org/library/papers/3114265PubMed
2457300Pathophysiological significance of the distribution of histamine receptor sub-types: a proposed dual role for histamine in inflammation and type I hypersensitivity reactions.Agents Actions1988https://conductscience.org/library/papers/2457300PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/86136

GET https://conductscience.org/api/papers/v1/86136/authors